CHU La Réunion
Saint-Denis, Reunion
Location status: Recruiting
Location contact
Catherine MARIMOUTOU, MD
CONTACT
262+ 262 90 50 27
Catherine MARIMOUTOU, MD
PRINCIPAL_INVESTIGATOR
Laetitia BERLY, PhD
CONTACT
NCT Number: NCT06473584
In view of the new priority given to diabetes in Réunion and the implementation of an ambitious plan to combat the disease at regional level, which includes the identification and management of pre-diabetes, the need for up-to-date data on the extent of these 2 diseases (diabetes and pre-diabetes) has become essential.
These two diseases have known risk factors: age, overweight, obesity, high waist circumference, family history, hypertension, eating habits and physical activity, all of which form part of a risk score for developing diabetes: the Findrisk recommended by the Haute Autorité de Santé for identifying people at risk of diabetes. Given the specific population characteristics of Réunion compared with Finland, where this score has been validated, it would seem important to be able to measure these risk indicators in the population as a function of carbohydrate status in order to check that the proposed thresholds are appropriate for the population of Réunion.
Finally, cardiovascular risk has been described as early as the pre-diabetes stage. Given the young age of onset of diabetes in Réunion and the high proportion of diagnoses of diabetes made following the occurrence of a cardiovascular complication, the study of the prognosis of carbohydrate status on the occurrence of complications using the social security information system will be offered on a voluntary basis to study subjects (via a probabilistic social security link).
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Saint-Denis, Reunion
Location status: Recruiting
Catherine MARIMOUTOU, MD
CONTACT
262+ 262 90 50 27
Catherine MARIMOUTOU, MD
PRINCIPAL_INVESTIGATOR
Laetitia BERLY, PhD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fasting glycemia on blood sample
Time frame: Day 1
Measurement of fasting blood glucose and blood glucose 2 hours after ingesting 75g of glucose (HGPO test) according to Haute Autorite de Sante (HAS) recommendations used in France for diagnosing diabetes and pre-diabetes in people with unknown diabetes
Contact information is provided by the study sponsor or research team.
Catherine MARIMOUTOU, MD, PhD
CONTACT
Florence LEFEBVRE D'HELLENCOURT
CONTACT
Centre Hospitalier Universitaire de la Réunion
Other
Acronym: PREVADIABRUN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05007990
Batten's Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bethesda, Maryland, United States
View Trial DetailsNCT00341237
Asthma, Bronchial Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT00071526
Diabetes, Diabetes Mellitus
Bethesda, Maryland, United States
View Trial DetailsNCT01399385
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial Details